Mineralys Stock

mineralystx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $159.18MM

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone levels. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension. The company has plans for the continued research and development of lorundrostat in hypertension and other potential indications. Mineralys Therapeutics was founded in 2019, and is headquartered in Radnor, Pennsylvania.

Register To Buy and Sell Shares

For more details on financing and valuation for Mineralys, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Mineralys’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Mineralys.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Jon Congleton
Chief Executive Officer
David Rodman, MD
Chief Medical Officer
Adam Levy
Chief Financial Officer & Chief Business Officer

Board Members

Olivier Litzka, PhD
Andera Partners
Derek DiRocco, PhD
RA Capital Management
Takeshi Takahashi
Catalys Pacific

News Highlights

Mineralys Therapeutics sets IPO target at up to $160M
The Main Line biopharmaceutical company stated in documents filed with the SEC that it plans to sell 10 million shares of common stock.
Updated on: Apr 14, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.